ASTRO Annual Meeting

Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new treatment options in oncology.

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed a machine learning tool designed to predict local failure after stereotactic radiosurgery for brain metastases.

Jeffrey Wong, MD, discusses findings on the use of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer presented at the 2024 American Society for Radiation Oncology Annual Meeting.

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.

In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow and lymphoid irradiation with cyclophosphamide and etoposide in high-risk acute leukemia.

Savita Dandapani, MD, PhD, discussed combining radium-223 and SBRT for metastatic castration-sensitive prostate cancer.

Chunhui Han, PhD, discusses what biology-guided radiotherapy is and how it differs from traditional radiotherapy techniques.

Percy Lee, MD, discussed findings from a trial evaluating a hypofractionated approach to concurrent chemoradiation, incorporating an adaptive stereotactic ablative radiotherapy boost in non–small cell lung cancer.

In an interview with Targeted Oncology, Chunhui Han, PhD, discussed the use of Ga 68 PSMA-11 for the imaging of metastatic sites in patients with prostate cancer.

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed research around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.

Alonso Gutierrez, MD, discusses the initial results from a feasibility study which evaluated the use of a daily wearable patient-tracking device to optimize radiation machine use and time the delivery of treatment.

Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy (H-RT) is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.

Puneeth Iyengar, MD, PhD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the two potential roles immunotherapy could play in the treatment of NSCLC.

Patients with low-risk meningioma had a 3-year progression-free survival (PFS) that modestly exceeded expectations after gross total resection followed by observation, results of a cooperative group trial showed.

Ann H. Klopp, MD, PhD, discusses the results of a recent trial comparing standard radiation to intensity-modulated radiation therapy (IMRT) in endometrial and cervical cancer, and what impact these results will have.

For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields (TTF) and employing a personalized transducer array, delivered electric field (EF) intensities that exceeded therapeutic intensities in 3 different tumor locations.

Results from a phase II study from Korea demonstrated high rates of tumor local control, overall survival (OS), and grade 1/2 gastrointestinal and hepatic toxicities in patients who received stereotactic body radiotherapy (SBRT) for unresectable hepatocellular carcinoma (HCC) after incomplete transarterial chemoembolization (TACE).

A strategy to stimulate an immune response in radiation-damaged tumor cells resulted in preliminary evidence of activity—including longer survival—in a small clinical trial of patients with metastatic breast cancer.

Patients with head and neck cancer whose disease is associated with <em>KRAS</em> variant had significantly better progression-free survival (PFS) and overall survival (OS) when treated with the monoclonal antibody cetuximab (Erbitux), according to findings of a retrospective analysis of a randomized trial.

Jim Zhong, MD, and colleagues describe a National Cancer Database (NCDB) outcomes analysis of patients with muscle invasive bladder cancer treated with either radical surgery or bladder preservation therapy.

The addition of external-beam radiotherapy (EBRT) to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease, interim data from a randomized trial showed.

According to findings from a multicenter randomized trial, chemoradiation for early-stage, low-grade follicular lymphoma led to significant improvement in progression-free survival (PFS) compared with involved-field radiotherapy alone (IFRT).

Pro-inflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti�CTLA-4 immunotherapy, ipilimumab.

Patients who had prostate cancer recurrence after radical prostatectomy lived significantly longer with the addition of hormonal therapy to salvage radiotherapy, long-term follow-up from a randomized trial showed.

Intensity-modulated radiation therapy (IMRT) for cervical cancer has led to a double-digit decrease in late bowel toxicity compared with 3-D conformal radiation therapy without statistical significance.

Ultra-hypofractionated radiation therapy for low-risk prostate cancer led to significantly lower rates of bowel and urinary dysfunction compared with patients treated with conventional radiotherapy regimens.

Dr. Erin Murphy talks about a study presented by Dr. Thomas E. Merchant regarding young patients with ependymoma and how they can be treated effectively with a regiment of adjuvant radiation.

Hypofractionated radiotherapy can achieve similar cure rates with similar side effects compared with conventional radiotherapy for men with low-risk, early prostate cancer, according to a recent study.

A phase III study shows noninferiority of accelerated partial breast irradiation as compared to conventional whole breast irradiation.

Minesh Mehta, MBChB, talks about the recently FDA-approved Optune used to treat newly diagnosed glioblastoma. The device utilizes alternating electric fields to inhibit tumor cell growth.